DIA Biosimilars 2013

Quotient Bioresearch

Quotient, KWS partner in antimicrobial drug discovery

Tuesday, May 10, 2011 12:25 PM

Two U.K.-based providers of early-stage and other drug development services, Quotient Bioresearch and KWS BioTest, have partnered to offer coordinated “plate to patient” support for clients engaged in the discovery and development of new antimicrobial agents, according to Pharma Times.

More... »

Cenduit: Now with Patient Reminders

Quotient Acquires GE’s Radio-labeling Business, Plans $24M Facility

Monday, July 13, 2009 07:00 AM

UK-based Quotient Bioresearch recently acquired Amersham Radiolabeling Service, the radiochemical synthesis operations of GE Healthcare, and plans to invest up to 15 million pounds ($24 million) in a state-of-the-art radiochemicals facility.

More... »

CRF Health – eCOA Forum

Quotient Bioresearch Acquires Edinburgh Facility

Tuesday, May 26, 2009 08:00 AM

U.K.-based Quotient Bioresearch acquired an Edinburgh clinical research facility to supplement the company’s growing clinical research business.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs